ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) P/S ratio
As of 25 September 2026, ResMed Inc. (RMD) trades at a P/S ratio of 5.7×. Over the past ten years it has ranged from 4.1× (January 2016) to 13.5× (September 2021); the current reading is higher than 31% of that period. That is above the Medical Instruments & Supplies industry median of 2.8× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2026 | 5.0× | (31.80%) |
| FY2025 | 7.4× | 25.39% |
| FY2024 | 5.9× | (22.75%) |
| FY2023 | 7.6× | (11.26%) |
| FY2022 | 8.6× | (23.63%) |
| FY2021 | 11.2× | 19.57% |
| FY2020 | 9.4× | 37.93% |
| FY2019 | 6.8× | 7.33% |
| FY2018 | 6.3× | 18.87% |
| FY2017 | 5.3× | 10.44% |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 5.0× | (14.86%) |
| Mar 2026 | 5.9× | (9.47%) |
| Dec 2025 | 6.5× | (14.50%) |
| Sep 2025 | 7.6× | 3.48% |
| 42 more quarters | Free account |
Against its own ten years
Low 4.1×
High 13.5×
Ten-year median
6.7×
Current reading's percentile
31
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| MDLN Medline Inc. compare | 1.0× |
| BAX Baxter International Inc. compare | 1.1× |
| SOLV Solventum Corporation compare | 1.9× |
| BDX Becton, Dickinson and Company compare | 2.3× |
| COO The Cooper Companies, Inc. compare | 2.5× |
| ALC Alcon compare | 2.9× |
| RMD ResMed Inc. | 5.7× |
| WST West Pharmaceutical Services, Inc. compare | 7.9× |
| RGEN Repligen Corporation compare | 13.6× |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on RMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement